Respiratory Syncytial Virus

The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.

New ACIP recommendations provide clarity, but questions linger for those aged 60 to 74 years.

The connection of F proteins could help destabilize the virus prior to infection of the next host.

A single dose RSV vaccine per year can offer optimal protection against 3 full RSV seasons.

RSV vaccination could be cost-effective among adults 60 years and older, with the ability to decrease vaccine costs and sustain efficacy.

Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.

Results displayed a non-inferior immune response of the co-administered vaccines, compared to administration in individual visits.

Programs can take several forms, including on-site clinics, voucher programs, and in-store events

RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.

Shared clinical decision-making presented drawbacks, resulting in age-based recommendations for adults aged 75 years and older and risk-based recommendations for individuals aged 60-74 years.

The findings further the understanding of respiratory virus immune evasion mechanisms and uncover how RSV-NS1 can target therapeutic intervention

Individuals with chronic conditions like asthma, diabetes, and chronic obstructive pulmonary disease face an increased risk of developing RSV.

The mRNA-1345 vaccine provides a one-off mechanism of protection because of its single-dose prefilled syringes

Educate patients about the importance of vaccination in preventing severe disease.

Providing immunization coadministration and assisting with insurance coverage are strategies to improve access.

Understanding preventive care reduces the risk of illnesses and decreases future costs.

Differentiating between the 3 available options can help identify which is best for individual patients.

Pharmacists’ awareness of respiratory syncytial virus and their role in educating about the vaccine have grown dramatically.

The ACIP recommendations are designed to improve access to RSV vaccination, emphasizing the need to get vaccinated.

Experts give important background information on respiratory syncytial virus (RSV), as well as the key clinical considerations that are associated with RSV vaccine use.

The recent approval could further the use of mRNA technology across other indications.

An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.

Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.

Data show that among individuals 60 years and older, the estimated rate of Guillain-Barré syndrome (GBS) after receiving an RSV vaccine was 5.0 and 1.5 per million doses of Abrysvo and Arexvy, respectively.

The 4-in-1 respiratory diagnostic test is either a single nasopharyngeal or anterior nasal swab that can confirm or rule out SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus with a single test.

The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk.

A single dose of the vaccine showed long-lasting protection against RSV-associated lower respiratory tract disease in older adults.

This is Moderna's second mRNA vaccine approval and the first mRNA vaccine approved for an indication other than COVID-19.

The study compares the safety and efficacy of mRNA-1345 compared to placebo.

Tools provide a safer testing option without using the viral proteins that cause infection.